Business
While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP-1 asset BT-001 into late-stage development, with two trials planned this year.
FEATURED STORIES
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The company’s overarching aim is to edit and equip cells with molecular tools, through CRISPR, to eliminate certain cancers.
There was a fair amount of clinical trial news last week. Here’s a look.
In his fifth year as CEO, his take-home was about $20.15 million – an almost $1.7 million base pay plus $13.5 million in stock awards, with another $5 million in incentive plan pay with “other” pay.
In 2019, Novartis subsidiary AveXis announced it acquired a manufacturing facility in Colorado to provide additional production capacity for Zolgensma. Just two years later, the facility will be closed and 400 people will be without a job.
Several new initial public offering (IPO) announcements have been made by international and U.S.-based biopharmaceutical and biotechnology companies in the past couple of days.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
On the back of a $135 million public offering in February, rare disease gene therapy company Krystal Biotech has launched subsidiary Jeune Inc. to promote its gene therapies for aesthetic skin conditions.
In a stunning fall from grace playing out this week, former Operation Warp Speed vaccine czar, Dr. Moncef Slaoui, issued a statement Thursday morning, as news emerged that he has resigned from additional biotech posts.
Lyell Immunopharma announced this week that it has completed construction of a $65 million, 70,000-square-foot LyFE Manufacturing Center, which the company will use to support clinical trials and meet cell therapy manufacturing needs.
Eliem Therapeutics emerged from stealth mode with $80 million in financing that will be used to develop therapeutics aimed at treating neuronal excitability disorders such as chronic pain, depression, epilepsy and anxiety.